| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | -0.2 | 6e-10 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.19 | 8e-09 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.17 | 3e-08 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | -0.2 | 3e-08 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | -0.2 | 5e-08 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.19 | 7e-08 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | -0.19 | 1e-07 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | -0.19 | 2e-07 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.18 | 2e-07 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | -0.19 | 2e-07 |